Aurobindo Pharma Limited

NSEI:AUROPHARMA Stock Report

Market Cap: ₹721.2b

Aurobindo Pharma Management

Management criteria checks 3/4

Aurobindo Pharma's CEO is Kambam Reddy, appointed in Jun 2006, has a tenure of 18.5 years. total yearly compensation is ₹45.05M, comprised of 50.9% salary and 49.1% bonuses, including company stock and options. directly owns 5.61% of the company’s shares, worth ₹40.49B. The average tenure of the management team and the board of directors is 9.6 years and 4.1 years respectively.

Key information

Kambam Reddy

Chief executive officer

₹45.0m

Total compensation

CEO salary percentage50.9%
CEO tenure18.5yrs
CEO ownership5.6%
Management average tenure9.6yrs
Board average tenure4.1yrs

Recent management updates

This Is Why Aurobindo Pharma Limited's (NSE:AUROPHARMA) CEO Can Expect A Bump Up In Their Pay Packet

Aug 23
This Is Why Aurobindo Pharma Limited's (NSE:AUROPHARMA) CEO Can Expect A Bump Up In Their Pay Packet

Recent updates

Is Aurobindo Pharma (NSE:AUROPHARMA) Using Too Much Debt?

Dec 18
Is Aurobindo Pharma (NSE:AUROPHARMA) Using Too Much Debt?

Earnings Miss: Aurobindo Pharma Limited Missed EPS By 14% And Analysts Are Revising Their Forecasts

Nov 12
Earnings Miss: Aurobindo Pharma Limited Missed EPS By 14% And Analysts Are Revising Their Forecasts

Insufficient Growth At Aurobindo Pharma Limited (NSE:AUROPHARMA) Hampers Share Price

Oct 20
Insufficient Growth At Aurobindo Pharma Limited (NSE:AUROPHARMA) Hampers Share Price

Estimating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)

Sep 10
Estimating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)

This Is Why Aurobindo Pharma Limited's (NSE:AUROPHARMA) CEO Can Expect A Bump Up In Their Pay Packet

Aug 23
This Is Why Aurobindo Pharma Limited's (NSE:AUROPHARMA) CEO Can Expect A Bump Up In Their Pay Packet

Earnings Update: Here's Why Analysts Just Lifted Their Aurobindo Pharma Limited (NSE:AUROPHARMA) Price Target To ₹1,422

Aug 13
Earnings Update: Here's Why Analysts Just Lifted Their Aurobindo Pharma Limited (NSE:AUROPHARMA) Price Target To ₹1,422

Here's Why Aurobindo Pharma (NSE:AUROPHARMA) Can Manage Its Debt Responsibly

Jun 20
Here's Why Aurobindo Pharma (NSE:AUROPHARMA) Can Manage Its Debt Responsibly

Aurobindo Pharma Limited (NSE:AUROPHARMA) Released Earnings Last Week And Analysts Lifted Their Price Target To ₹1,271

May 29
Aurobindo Pharma Limited (NSE:AUROPHARMA) Released Earnings Last Week And Analysts Lifted Their Price Target To ₹1,271

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value

May 22
Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value

Aurobindo Pharma Limited's (NSE:AUROPHARMA) Earnings Are Not Doing Enough For Some Investors

Apr 10
Aurobindo Pharma Limited's (NSE:AUROPHARMA) Earnings Are Not Doing Enough For Some Investors

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Worth ₹1.1k Based On Its Intrinsic Value?

Jan 14
Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Worth ₹1.1k Based On Its Intrinsic Value?

Aurobindo Pharma (NSE:AUROPHARMA) Has A Pretty Healthy Balance Sheet

Dec 27
Aurobindo Pharma (NSE:AUROPHARMA) Has A Pretty Healthy Balance Sheet

CEO Compensation Analysis

How has Kambam Reddy's remuneration changed compared to Aurobindo Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

₹36b

Jun 30 2024n/an/a

₹35b

Mar 31 2024₹45m₹23m

₹32b

Dec 31 2023n/an/a

₹28b

Sep 30 2023n/an/a

₹23b

Jun 30 2023n/an/a

₹20b

Mar 31 2023₹37m₹19m

₹19b

Dec 31 2022n/an/a

₹20b

Sep 30 2022n/an/a

₹21b

Jun 30 2022n/an/a

₹24b

Mar 31 2022₹27m₹14m

₹26b

Dec 31 2021n/an/a

₹29b

Sep 30 2021n/an/a

₹52b

Jun 30 2021n/an/a

₹53b

Mar 31 2021₹23m₹20m

₹53b

Dec 31 2020n/an/a

₹54b

Sep 30 2020n/an/a

₹31b

Jun 30 2020n/an/a

₹30b

Mar 31 2020₹15m₹13m

₹28b

Dec 31 2019n/an/a

₹26b

Sep 30 2019n/an/a

₹26b

Jun 30 2019n/an/a

₹25b

Mar 31 2019₹15m₹13m

₹24b

Dec 31 2018n/an/a

₹23b

Sep 30 2018n/an/a

₹22b

Jun 30 2018n/an/a

₹24b

Mar 31 2018₹15m₹13m

₹24b

Compensation vs Market: Kambam's total compensation ($USD530.22K) is about average for companies of similar size in the Indian market ($USD724.01K).

Compensation vs Earnings: Kambam's compensation has increased by more than 20% in the past year.

CEO

Kambam Reddy (66 yo)

18.5yrs

Tenure

₹45,048,542

Compensation

Mr. Kambam Nithyananda Reddy has been Vice Chairman of Aurobindo Pharma Limited since June 1, 2012 and serves as a Whole Time Director of Aurobindo Pharma Limited since December 26, 1986 and serves as Mana...

Leadership Team

NamePositionTenureCompensationOwnership
Kambam Reddy
Vice Chairman & MD18.5yrs₹45.05m5.61%
₹ 40.5b
Mettu Madan Reddy
Whole-Time Directorno data₹60.15mno data
Makkapati Satakarni
President of Biologics8.8yrs₹300.00kno data
Santhanam Subramanian
Chief Financial Officer10.4yrs₹21.06mno data
S. Kumar
President of Technicalno datano datano data
B. Reddy
Compliance Officer & Company Secretary8.5yrs₹4.76mno data
G. Prasad
Senior Vice President of Global Finance & Operationsno datano datano data
Sudhir Singhi
Head of Global Finance Operationsno datano datano data
A. Rama Rao
Chief Quality Officer -Corporate QAno datano data0.025%
₹ 177.6m
V. Handa
President of Chemical Researchno datano datano data
Gita Rao
President of RAD-IIno data₹9.14mno data
Hemant Sharma
President-ARDno data₹10.09mno data

9.6yrs

Average Tenure

60yo

Average Age

Experienced Management: AUROPHARMA's management team is seasoned and experienced (9.6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Kambam Reddy
Vice Chairman & MD38yrs₹45.05m5.61%
₹ 40.5b
Mettu Madan Reddy
Whole-Time Director18.3yrs₹60.15mno data
Makkapati Satakarni
President of Biologicsless than a year₹300.00kno data
Penaka Venkata Reddy
Non-Executive Director38yrs₹600.00k3.07%
₹ 22.1b
Penaka Sarath Reddy
Non-Executive Director17.3yrs₹900.00kno data
Santanu Mukherjee
Independent Director1.8yrs₹2.50mno data
Deepali Pant Joshi
Independent Directorno data₹500.00kno data
Venkat Chalasani
Independent Director of Apitoria Pharma Private Limited1.7yrsno datano data
Mangalam Kumar
Independent Non-Executive Chairmanless than a yearno datano data
Girish Vanvari
Non-Executive Independent Director4.1yrs₹2.60mno data

4.1yrs

Average Tenure

63.5yo

Average Age

Experienced Board: AUROPHARMA's board of directors are considered experienced (4.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 04:21
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Aurobindo Pharma Limited is covered by 54 analysts. 28 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Meeta ShettyAsian Markets Securities Private Limited
Kamlesh KotakAsian Markets Securities Private Limited
Harith AhamedAvendus Spark